Jacobs Solutions Inc. (NYSE:J) on Thursday announced that Sanofi (NASDAQ:SNY) selected the company to provide engineering, procurement, and construction management services for a new insulin manufacturing facility in Frankfurt, Germany.
Jacobs Secures Sanofi Manufacturing Contract
The facility, located alongside Sanofi’s existing insulin manufacturing campus, will support production of multiple insulin products and strengthen supply reliability.
Jacobs will oversee design, procurement, construction management and commissioning, using existing site infrastructure and advanced manufacturing technologies.
Earlier this year, Engineering News-Record ranked Jacobs the No. 1 Pharmaceuticals Design Firm. The company also provides EPCM services for FUJIFILM Biotechnologies’ $3.2 billion Holly Springs campus.
Jacobs Announces Recent Airport and Rail Contracts
On Nov. 17, Jacobs announced a five-year contract with the Metropolitan Washington Airports Authority to support modernization projects at Washington Dulles International Airport and Ronald Reagan Washington National Airport.
The agreement covers engineering oversight, project controls and construction management, with options for extensions.
On Nov. 13, Jacobs and AECOM announced their appointment to Irish Rail’s multidisciplinary consultancy framework.
Their joint venture also secured the framework’s first project, the Limerick–Limerick Junction rail upgrade, covering engineering, design, environmental assessment and project delivery services.
See More:
Top Value Stocks
Earnings Preview and Analyst Outlook
Jacobs Solutions is scheduled to report earnings on Nov. 23, 2026.
Analysts expect earnings per share of $2.13, compared with $1.75 a year earlier, while revenue is projected at $2.56 billion, down from $3.15 billion.
Jacobs carries a consensus Buy rating, with an average analyst price forecast of $171.
Citigroup maintained its Buy rating and raised its price forecast to $188 on Oct. 23. KeyBanc lowered its forecast to $166 while maintaining an Overweight rating on Oct. 15, while Truist Securities cut its forecast to $160 and maintained a Hold rating on Oct. 5.
Technical Analysis
Jacobs Solutions maintains a bullish technical setup, trading above its key moving averages. The 20-day SMA remains above the 50-day SMA, while an August golden cross—when the 50-day SMA crossed above the 200-day SMA—reinforces the upward trend.
The Relative Strength Index (RSI) stands at 59.32, indicating neutral-to-bullish momentum without overbought conditions. The MACD also remains above its signal line, supporting the positive trend.
With no clearly defined support or resistance levels, traders may watch previous swing highs and lows for potential breakouts or reversals.
Jacobs shares have gained 8.40% over the past 12 months, reflecting positive longer-term price performance.
Benzinga Edge Rankings
Jacobs Solutions’ Benzinga Edge scores highlight strong Momentum at 88.26, contrasting with weaker Quality (22.33), Value (19.50) and Growth (8.82) scores.
The rankings indicate strong stock price momentum despite weaker fundamental metrics, putting earnings and guidance in focus ahead of the company’s upcoming results.
J Price Action: Jacobs Solutions shares closed 0.63% lower at $157.24 on Wednesday, according to Benzinga Pro data.
Photo: T. Schneider via Shutterstock
